Literature DB >> 11284448

Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.

G De Sarro1, E D Di Paola, G Conte, M P Pasculli, A De Sarro.   

Abstract

Retigabine (D-2319, 0.5-20 mg/kg i.p.) antagonised dose dependently audiogenic seizures in DBA/2 mice. Retigabine at 0.5 mg/kg i.p., a dose that per se did not affect the occurrence of audiogenic seizures significantly, potentiated the anticonvulsant activity of carbamazepine, diazepam, felbamate, lamotrigine, phenytoin, phenobarbital and valproate against sound-induced seizures in DBA/2 mice. The degree of additivity for the effect induced by retigabine was greatest for diazepam, phenobarbital, phenytoin and valproate, less for carbamazepine and lamotrigine and least for felbamate. The increase in anticonvulsant activity was usually associated with a comparable increase in motor impairment. However, the therapeutic index of combined treatment (drugs plus retigabine), was more favourable than the same drug plus vehicle. Since retigabine had no significant influence on the total and free plasma levels of the anticonvulsant drugs, pharmacokinetic interactions, in terms of total or free plasma levels, are not probable. However, the possibility that retigabine modifies the clearance of the anticonvulsant drugs from the brain cannot be excluded. Retigabine had no significant effect on the hypothermic effects of the anticonvulsants tested. In conclusion, retigabine showed an additive effect when administered in combination with classical anticonvulsants, most notably diazepam, phenobarbital, phenytoin and valproate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284448     DOI: 10.1007/s002100000361

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  7 in total

1.  Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Gabriela Mora; Ricardo Tapia
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

2.  Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.

Authors:  Geraldine M Ferron; Alain Patat; Virginia Parks; Paul Rolan; Steven M Troy
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

3.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

4.  Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures.

Authors:  Judith Lz Weisenberg; Michael Wong
Journal:  Neuropsychiatr Dis Treat       Date:  2011-07-07       Impact factor: 2.570

5.  Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.

Authors:  Vincenzo Barrese; Francesco Miceli; Maria Virginia Soldovieri; Paolo Ambrosino; Fabio Arturo Iannotti; Maria Roberta Cilio; Maurizio Taglialatela
Journal:  Clin Pharmacol       Date:  2010-12-07

6.  Clinical utility of adjunctive retigabine in partial onset seizures in adults.

Authors:  Konrad Rejdak; Jarogniew J Luszczki; Barbara Błaszczyk; Roman Chwedorowicz; Stanislaw J Czuczwar
Journal:  Ther Clin Risk Manag       Date:  2012-01-20       Impact factor: 2.423

7.  Efficacy of Retigabine on Acute Limbic Seizures in Adult Rats.

Authors:  L K Friedman; A M Slomko; J P Wongvravit; Z Naseer; S Hu; W Y Wan; S S Ali
Journal:  J Epilepsy Res       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.